The cannabinoid CB(2) receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence

Documenti analoghi

• Positive Allosteric Modulation of CB(1) Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward
  di: Slivicki, Richard A., et al.
  Pubblicazione: (2020)
• Slowly Signaling G Protein–Biased CB(2) Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence
  di: Lin, Xiaoyan, et al.
  Pubblicazione: (2018)
• Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit
  di: Slivicki, Richard A., et al.
  Pubblicazione: (2018)
• Activation of cannabinoid CB(1) and CB(2) receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats
  di: Rahn, E J, et al.
  Pubblicazione: (2007)
• Self-medication of a cannabinoid CB(2) agonist in an animal model of neuropathic pain
  di: Gutierrez, Tannia, et al.
  Pubblicazione: (2011)